Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Daniel L. Lohse"'
Autor:
Taylor Buckley, Kei Hiraoka, Ryan Burnett, Akihito Inagaki, Christopher R. Logg, Cindy Burrascano, Douglas J. Jolly, Carlos E. Ibanez, Daniel L. Lohse, Karin Kristina Amundson, Dawn Jolson, Oscar Diago, Noriyuki Kasahara, Amy Lin, Omar D. Perez, Harry E. Gruber
Publikováno v:
Molecular Therapy. 20:1689-1698
Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86f44f7b56c4cb27af1bcdd855b5f22e
https://doi.org/10.1038/mt.2012.83
https://doi.org/10.1038/mt.2012.83
Autor:
Joel Renick, Jianguo Cao, Michael D. Martin, John Doukas, Ahmed A Kousba, Binqi Zeng, John Hood, Steven Hu, Daniel L. Lohse, Xiyun Yu, Arek Tabak, Glenn Noronha, Shiyin Yee, Richard Soll, Andrew McPherson
Publikováno v:
Drug Metabolism and Disposition. 35:929-936
TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) is a novel multitargeted, orally active protein tyrosine kinase inhibitor. The inhibition constants (K(i)) of TG100435 against Src, Lyn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b6bed385d6162f4cb1f1e10ac6eb826
https://doi.org/10.1124/dmd.106.014290
https://doi.org/10.1124/dmd.106.014290
Autor:
Chi Ching Mak, Xianchang Gong, Elena Dneprovskaia, Andrew McPherson, Ved P. Pathak, J. Hood, Binqi Zeng, Boris Klebansky, Richard M. Fine, W. Liao, Wolfgang Wrasidlo, Glenn Noronha, Joel Renick, Ningning Zhao, Y. Zhou, Kathy Barrett, Colleen Gritzen, Moorthy S. S. Palanki, Xinshan Kang, Ge Li, Ute Splittgerber, Richard M. Soll, Daniel L. Lohse, Jianguo Cao
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 16:5546-5550
We report the discovery and preliminary SAR studies of a series of structurally novel benzotriazine core based small molecules as inhibitors of Src kinase. To the best of our knowledge, benzotriazine template based compounds have not been reported as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77c3a59d9d64cb5d6108ec85b738a7b4
https://doi.org/10.1016/j.bmcl.2006.08.035
https://doi.org/10.1016/j.bmcl.2006.08.035
Publikováno v:
Proceedings of the National Academy of Sciences. 93:2493-2498
Engineering site-specific amino acid substitutions into the protein-tyrosine phosphatase (PTPase) PTP1 and the dual-specific vaccinia H1-related phosphatase (VHR), has kinetically isolated the two chemical steps of the reaction and provided a rare op
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b668fe0c5ce5b9821847d690b6b49d5
https://doi.org/10.1073/pnas.93.6.2493
https://doi.org/10.1073/pnas.93.6.2493
Publikováno v:
Structure. 3:987-990
The crystal structures of serine/threonine phosphatases provide the basis for understanding their inhibition by physiologically relevant compounds such as microcystin, cyclosporin and FK506. The structures also highlight the importance of a common se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54ba1a0a38c86dd2ec7eb6065fd35e04
https://doi.org/10.1016/s0969-2126(01)00234-9
https://doi.org/10.1016/s0969-2126(01)00234-9
Autor:
Elena Dneprovskaia, Daniel L. Lohse, Richard Soll, Andrew McPherson, Chi Ching Mak, John Hood, Boris Klebansky, Richard M. Fine, Joel Renick, Jianguo Cao, Chun P. Chow, Moorthy S. S. Palanki, Glenn Noronha, Ved P. Pathak, Binqi Zeng, Xinshan Kang
Publikováno v:
Current topics in medicinal chemistry. 8(10)
Chronic myelogenous leukemia (CML) is a hematological stem cell disorder caused by increased and unregulated growth of myeloid cells in the bone marrow, and the accumulation of excessive white blood cells. Abelson tyrosine kinase (ABL) is a non-recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12165fa94b4010e1abb10fefa72becb6
https://pubmed.ncbi.nlm.nih.gov/18673174
https://pubmed.ncbi.nlm.nih.gov/18673174
Autor:
Shiyin Yee, John Doukas, Wolfgang Wrasidlo, Michael D. Martin, Hong Zhu, John Hood, Moorthy S. S. Palanki, Daniel L. Lohse, Glenn Noronha, Richard Soll, Xinshan Kang, Richard M. Fine, Elena Dneprovskaia
Publikováno v:
Journal of medicinal chemistry. 50(18)
In studies aimed toward identifying effective and safe inhibitors of kinase signaling cascades that underlie ischemia/reperfusion (I/R) injury, we synthesized a series of pteridines and pyridopyrazines. The design strategy was inspired by the examina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a9556434a69a57d5e8f096abf079df2
https://pubmed.ncbi.nlm.nih.gov/17685602
https://pubmed.ncbi.nlm.nih.gov/17685602
Autor:
Chi Ching Mak, Richard E. Fine, Andrew McPherson, John Hood, Daniel L. Lohse, Moorthy S. S. Palanki, Xinshan Kang, Colleen Gritzen, Boris Klebansky, Ved P. Pathak, Joel Renick, Richard Soll, Jianguo Cao, Binqi Zeng, Hong Zhu, Glenn Noronha
Publikováno v:
Bioorganicmedicinal chemistry letters. 17(21)
We describe the design, synthesis and structure-activity relationship studies in optimizing a series of benzotriazine compounds as potent inhibitors of both Abl and Abl-T315I enzymes. The design includes targeting of an acid functional residue on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9487248cf8bfc4677744d54717e2e8d8
https://pubmed.ncbi.nlm.nih.gov/17827012
https://pubmed.ncbi.nlm.nih.gov/17827012
Autor:
Steven X, Hu, Richard, Soll, Shiyin, Yee, Daniel L, Lohse, Ahmed, Kousba, Binqi, Zeng, Xiyun, Yu, Andrew, McPherson, Joel, Renick, Jianguo, Cao, Arek, Tabak, John, Hood, John, Doukas, Glenn, Noronha, Michael, Martin
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 35(6)
TG100435 ([7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine) is a novel multitargeted, orally active protein tyrosine kinase inhibitor. The inhibition constants (K(i)) of TG100435 against Src, Lyn
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8c7981b80db1a74ec1e48f4001aefc4f
https://pubmed.ncbi.nlm.nih.gov/17371799
https://pubmed.ncbi.nlm.nih.gov/17371799
Autor:
John Doukas, Xianchang Gong, Andrew McPherson, Suhan Tang, Glenn Noronha, Tessa Brodhag, Daniel L. Lohse, Antonio Boccia, Moorthy S. S. Palanki, Ehab Y. Hanna, Hong Gu, Kathy Barrett, Colleen Gritzen, Shiyin Yee, Hong Zhu, Ningning Zhao, Chi Ching Mak, Elena Dneprovskaia, Ute Splittgerber, Chun P. Chow, Ge Li, Richard E. Fine, Jianguo Cao, Feng Shi, Richard Soll, Xinshan Kang, Steven Hu, Silva Stoughton, Jann Key, Ved P. Pathak, Binqi Zeng, Ahmed A Kousba, John Hood, Boris Klebansky, Joel Renick
Publikováno v:
Bioorganicmedicinal chemistry letters. 17(3)
We describe the identification of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine (3), a potent, orally active Src inhibitor with desirable PK properties, demonstrated activity in human tumor cell l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c457d51e7ad2328a70dfc66c65cdf94c
https://pubmed.ncbi.nlm.nih.gov/17113292
https://pubmed.ncbi.nlm.nih.gov/17113292